AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has raised $3.25 million CAD in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners.
AmacaThera Secures Funding to Initiate Phase I Trial of Non-Opioid Pain Control Therapeutic
Previous
Previous
Apply for the SmartStart Seed Fund Program
Next
Next